Business
Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2023 and Provides Corporate Update
- Patient enrollment has commenced in landmark pivotal trial for lead product candidate, FemBloc® - Three product approvals achieved in Canada for FemaSeed®,
About this update from Femasys Inc.
[{"type":"text","content":" - Patient enrollment has commenced in landmark pivotal trial for lead product candidate, FemBloc® - Three product approvals achieved in Canada for FemaSeed®, FemCerv® and FemCath® products during the second quarter - Raised $3.9 million in a registered direct offering ATLANTA, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting women’s unmet needs worldwide by developing a broad portfolio of innovative product candidates and products that include minimally invasive, in-office technologies for reproductive health, today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update. “The past quarter, we made significant, notable progress on all fronts to advance our synergistic programs in women’s health – from ushering forward the clinical development of our lead product candidates to broadening access to our complimentary diagnostic products by gaining additional commercial approvals,” said Kathy Lee-Sepsick, founder, president and chief executive officer of Femasys. “We continue to successfully advance our lead product FemBloc for permanent birth control through the regulatory process with achievement of Investigational Device Exemption (IDE) approval from the United States Food and Drug Administration (FDA) for the landmark pivotal trial. Thereafter, we were very pleased to announce the rapid initiation of enrollment in this trial, a very important milestone achieved for Femasys, brining us closer to making this much needed non-surgical alternative available to women.” Ms. Lee-Sepsick, continued, “Of note this quarter, we received three new product approvals in Canada, including for FemaSeed, the first-ever, first-line approach designed to deliver sperm directly where conception occurs, broadening our commercial offerings, as we strive to bring safe, accessible novel options to women. We are exploring potential partnerships to maximize the value of our approved and available assets as we remain focused on prioritizing our use of capital on advancing our critical product candidates to ensure continued progress.” Second Quarter 2023 and Recent Corporate Highlights: In August, Femasys announced the initiation of enrollment in a prospective multi-center pivotal trial for FemBloc INtratubal Occlusion for TranscervicAL PErmanent Birth Contr...